VANDETANIB

IUPAC name:

N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl) methoxy]quinazolin-4-amine

CAS No.

443913-73-3

Molecular Weight:

475.4 g.mol−1

Molecular Formula:

C22H24BrFN4O2

Granule:

Available - Ready to press

Mechanism Of Action:

Vandetanib is a selective and potent inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (RE-arranged during Transfection) tyrosine kinases.

EGFR- and VEGFR-dependent signaling are both clinically validated pathways in cancer, including non-small-cell lung cancer. RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer led to orphan-drug designation by the regulatory authorities in the USA and EU.

Indication:

It indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

Use in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks.

information

Category: Oncology

January 21, 2024

Lenvatinib Mesylate

Oncology

Cas No: 857890-39-2

Mechanism Of Action: Lenvatinib is classified as a receptor tyrosine kinase (RTK) inhibitor that effectively suppresses the kinase activities of vascular endothelial growth factor (VEGF)

TRAMETINIB DIMETHYL SULFOXIDE

Oncology

Cas No: 1187431-43-1

Mechanism Of Action: Trametinib is identified as a reversible and remarkably selective allosteric inhibitor of MEK1 and MEK2. Through its high-affinity binding to unphosphorylated MEK1

DABRAFENIB MESYLATE

Oncology

Cas No: 1195768-06-9

Mechanism Of Action: Dabrafenib is recognized as a competitive and highly selective inhibitor of BRAF. Its mechanism of action involves binding to the ATP pocket

Abemaciclib

Oncology

Cas No: 1231929-97-7

Mechanism Of Action: Abemaciclib demonstrates high selectivity in inhibiting CDK4 and CDK6 with potent activity in the low nanomolar range. By inhibiting the phosphorylation of

Sacubitril-Valsartan

Cardiovascular

Cas No: 936623-90-4

Mechanism Of Action: Sacubitril/valsartan is a medication that exerts its effects through the dual inhibition of neprilysin, an enzyme responsible for degrading certain peptides, and

Roxadustat

Anti-Anemic

Cas No: 808118-40-3

Mechanism Of Action: Anemia is a common complication of chronic kidney disease that can be caused by reduced production of renal erythropoietin (EPO), functional iron